CFO Mowry purchases 15,000 shares of NAUT at $0.77; stock -76.3% from 52-week high, company unprofitable
CFO and Treasurer Anna Mowry purchased 15,000 shares at $0.77 on 2025-05-29, increasing her holdings by 22.1% to 83,000 shares total. The transaction occurs against a backdrop of significant distress: Nautilus Biotechnology reported net income of $-16,613,000.00 in its most recent full fiscal year, and the stock trades at $0.73, representing a -76.3% decline from its 52-week high of $3.08. The purchase at $0.77 represents the CFO's open-market acquisition of equity during a period of substantial operational losses and depressed valuation relative to recent history. Investors should note the wide variance between transaction price ($0.77) and current price ($0.73), as well as the 90-day decline of -39.7%, suggesting continued deterioration in market confidence.